Boardroom Alpha
Boardroom Alpha
ENOV · Current Report (Form 8-K) · Filed December 10, 2025

Enovis Corp — Current Report (Form 8-K)

Form
8-K
Filed
December 10, 2025
Period
Dec 8, 2025
Ticker
ENOV
Accession
0001493152-25-027007
Boardroom Alpha · Filing insights

Enovis amends its credit agreement, extending maturity and relaxing covenants while adding lenders.

About Enovis Corp
Market cap
$1.4B
1Y TSR
−8.6%
3Y TSR
−22.4%
Board grade
C-
Sector
Healthcare
CEO
Damien McDonald
Last annual meeting: May 19, 2026 · View full Enovis Corp profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 8, 2025

 

 

 

Enovis Corporation

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-34045   54-1887631
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)

 

2711 Centerville Road, Suite 400

Wilmington, DE 19808

(Address of principal executive offices) (Zip Code)

 

(302) 252-9160

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   ENOV   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On December 8, 2025, Enovis Corporation, a Delaware corporation (the “Company”), entered into Amendment No. 3 (the “Third Amendment”) to the Credit Agreement, dated April 4, 2022 (as amended by Amendment No. 1 to Credit Agreement, dated October 23, 2023 and Amendment No. 2 to Credit Agreement, dated March 28, 2024, the “Existing Credit Agreement,” and the Existing Credit Agreement, as amended by the Third Amendment, the “Amended Credit Agreement”), by and among the Company, certain subsidiaries of the Company identified therein as guarantors, each of the lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as administrative agent.

 

The Amended Credit Agreement provides for a revolving credit facility of up to $1.1 billion (the “Revolving Facility” and the loans thereunder, the “Revolving Loans”) and a term loan facility of $700.0 million (the “Term Loan Facility” and the loans thereunder, the “Term Loans”). The Third Amendment extended the maturity date for all outstanding Revolving Loans and Term Loans to December 8, 2030 (the “Maturity Date”); provided, however, that in the event that 91 days prior to such Maturity Date, the Company’s liquidity (calculated as set forth in the Amended Credit Agreement, based on the Company’s and its subsidiaries’ unrestricted, unencumbered and freely transferrable cash and cash equivalents, plus the aggregate amount of available unused revolving commitments under the Revolving Facility) is less than 125% of the then-outstanding principal balance of the Company’s senior unsecured convertible notes, then all outstanding Revolving Loans and Term Loans will mature on the date that is 91 days prior to the Maturity Date.

 

Consistent with the Existing Credit Agreement, the Amended Credit Agreement provides that the Company must maintain a Senior Secured Leverage Ratio (as defined in the Amended Credit Agreement) of at least 3.50 to 1.00, but provides for a temporary increase in the maximum Senior Secured Leverage Ratio threshold, at the election of the Company and subject to certain conditions, following one or more acquisitions for which the aggregate consideration is $300.0 million or more. Under the Existing Credit Agreement, such temporary increase in the maximum Senior Secured Leverage Ratio threshold was available following one or more acquisitions for which the aggregate consideration was $500.0 million or more. The Third Amendment also increased the maximum amount of unrestricted, unencumbered and freely transferrable cash and cash equivalents that may be applied to offset the amount of indebtedness used in the calculations of the Senior Secured Leverage Ratio and the Total Leverage Ratio (as defined in the Amended Credit Agreement). Pursuant to the Amended Credit Agreement, the amount of indebtedness used in such calculations may be reduced by up to $400.0 million of the Company’s and its subsidiaries’ unrestricted, unencumbered and freely transferrable cash and cash equivalents, compared to $150.0 million under the Existing Credit Agreement. Further, the Third Amendment (i) reduced the applicable margin for borrowings if the Total Leverage Ratio (as defined in the Amended Credit Agreement) is less than 1.50 to 1.00 and (ii) modified certain negative covenants to increase the maximum consideration payable for a permitted acquisition from $150.0 million to $200.0 million and increased baskets available for additional debt.

 

In addition, in connection with the Third Amendment, each of Truist Bank, DNB Capital LLC and Sumitomo Mitsui Banking Corporation became a lender under the Amended Credit Agreement.

 

A portion of the proceeds from the Term Loan Facility was used to repay approximately $335.0 million of the outstanding principal balance under the Revolving Facility. Accordingly, as of December 8, 2025, after giving effect to the Third Amendment, $167.0 million of principal was outstanding under the Revolving Facility and $700.0 million of principal was outstanding under the Term Loan Facility.

 

The lenders that are parties to the Amended Credit Agreement and their respective affiliates are full-service financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage, and other financial and non-financial activities and services. Certain of these financial institutions and their respective affiliates have provided, and may in the future provide, certain of these services to the Company and its subsidiaries and to persons and entities with relationships with the Company and its subsidiaries, for which they received or will receive customary fees and expenses.

 

The foregoing description of the Third Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Third Amendment, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

 

 

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

10.1#   Amendment No. 3 to Credit Agreement, dated as of December 8, 2025, by and among the Company, the lenders and guarantors party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent.
104   Cover Page Interactive Data File - The cover page from this Current Report on Form 8-K is formatted in Inline XBRL.

 

#   Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish to the Securities and Exchange Commission a copy of any omitted schedule or exhibit upon request.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 10, 2025    
     
  ENOVIS CORPORATION
     
  By:

/s/ Bradley J. Tandy

  Name: Bradley J. Tandy
  Title: Senior Vice President and Chief Legal Officer

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Enovis Corp (ENOV)

Reference

Frequently asked questions

When did Enovis Corp file this 8-K?
Enovis Corp (ENOV) filed this Current Report (Form 8-K) with the SEC on December 10, 2025. The accession number assigned by EDGAR is 0001493152-25-027007.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Enovis amends its credit agreement, extending maturity and relaxing covenants while adding lenders. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Enovis Corp's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Enovis Corp has filed under CIK 1420800, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer